查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1615476

HIV 临床试验市场：按阶段、试验设计、介入类型、市场参与企业、赞助商 – 2025-2030 年全球预测

HIV Clinical Trials Market by Phase (Phase I, Phase II, Phase III), Study Design (Expanded Access Studies, Interventional Studies, Observational Studies), Type of Intervention, Participant, Sponsor - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，HIV临床试验市场价值为11.5亿美元，预计到2024年将达到12.3亿美元，复合年增长率为7.20%，到2030年预计将达到18.8亿美元。

HIV 临床试验市场包括旨在开发、测试和改善 HIV 及相关疾病的治疗方法和预防的各种试验。这些试验的范围包括评估新的抗逆转录病毒、疫苗和临床实验治疗的安全性和有效性，以改善患者的治疗结果，并朝着潜在的治癒和功能缓解迈进。全球爱滋病毒流行、不断变化的病毒格局和抗药性模式凸显了爱滋病毒临床试验的必要性，这需要不断创新和调整治疗方法。 HIV 临床试验开发跨越各个阶段，从药物开发和概念验证研究的早期阶段到专注于比较长期安全性和有效性的后期研究。最终的使用范围扩展到寻求实施循证治疗通讯协定的药物开发商、医疗保健提供者、研究机构和政策制定者。

主要市场统计
基准年[2023] 11.5亿美元
预计年份 [2024] 12.3亿美元
预测年份 [2030] 18.8亿美元
复合年增长率（%） 7.20%

该市场受到生物技术进步、公共和私人资金增加以及对爱滋病毒认识不断提高等因素的支持。潜在的发展机会包括利用基因组资料开发个人化医疗方法以及探索新型疫苗平台和长效抗逆转录病毒药物。然而，高昂的研究成本、监管障碍、临床实验人群的伦理考量以及潜在的招募困难等限制因素构成了重大障碍。创新可以在诸如用于试验资料分析的机器学习、使用虚拟或分散方法纳入以患者为中心的试验设计以及探索潜在的协同效应联合治疗等领域发展。

关键的市场成长要素包括人口变化，特别是在高发病率地区，以及强调治疗和预防的综合护理模式的兴起。公司可以透过投资与学术机构和患者倡导团体的伙伴关係来增强信任并推动临床试验的註册，从而受益。总体而言，动态变化的市场动态需要不断的研究和策略调整，以有效地利用技术进步和患者需求。

市场动态：揭示快速发展的爱滋病毒临床试验市场的关键市场洞察

供需的动态交互作用正在改变爱滋病毒临床试验市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球爱滋病发病率不断上升
    • 製药公司和非营利组织增加对爱滋病毒临床试验的投资
  • 市场限制因素
    • 与 HIV 临床试验和相关研发成本相关的高成本
  • 市场机会
    • 政府增加爱滋病毒治疗和药物的核准
    • HIV临床试验技术和解决方案的进展
  • 市场挑战
    • HIV 临床试验制定的复杂性

波特五力：引领爱滋病毒临床试验市场的策略工具

波特的五力架构是了解爱滋病毒临床试验市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 HIV 临床试验市场的外部影响

外部宏观环境因素在塑造爱滋病毒临床试验市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 HIV 临床试验市场的竞争格局

HIV 临床试验市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 HIV 临床试验市场供应商的绩效评估

FPNV定位矩阵是评估HIV临床试验市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划爱滋病毒临床试验市场的成功之路

HIV 临床试验市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界各地感染爱滋病的人数不断增加
      • 製药公司和非营利组织增加了对爱滋病毒临床试验的投资活动
    • 抑制因素
      • HIV 临床试验和相关研发成本相关的高成本
    • 机会
      • 政府增加爱滋病毒治疗和药物的核准
      • HIV临床试验技术和解决方案的进展
    • 任务
      • HIV 临床试验药物处方的复杂性
  • 市场区隔分析
    • 阶段：增加 III 期临床试验的数量，以提供新的治疗方法
    • 赞助：增加製药和生物製药公司的赞助，以提高药品的商业性可用性
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 HIV 临床试验市场：依阶段、研究设计、介入类型、市场阶段

  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 第四阶段

第七章 HIV 临床试验市场：阶段、试验设计、介入类型、市场研究设计

  • 扩大访问研究
  • 干预研究
  • 观察性研究

第八章 HIV 临床试验市场：依阶段、试验设计、介入类型、市场介入类型

  • 药物治疗
  • 疫苗

第九章 HIV 临床试验市场：依阶段、研究设计、介入类型和市场参与企业

  • 成人
  • 小儿科
  • 孕妇

第 10 章 HIV 临床试验市场：阶段、试验设计、介入类型、市场赞助商

  • 非营利组织
  • 製药和生物製药公司

第十一章美洲爱滋病毒临床试验市场：阶段、试验设计、介入类型、市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区爱滋病毒临床试验市场：阶段、研究设计、介入类型、市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第 13 章：欧洲、中东和非洲 HIV 临床试验市场：阶段、研究设计、介入类型和市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 爱滋病临床试验小组的临床试验旨在提高爱滋病毒治疗的有效性和安全性
    • 研究表明，在不同人群中，注射卡博特韦在预防爱滋病毒方面优于口服 PrEP。
    • ReiThera、Ragon Institute 和 IAVI 开始创新 T 细胞 HIV 疫苗 HIVconsvX 的 I 期试验
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • American Gene Technologies Inc
  • AstraZeneca PLC
  • Bayer AG
  • BioNTech SE
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • CSL Limited
  • Daiichi Sankyo Company, Limited
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Janssen Pharmaceuticals, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7C50F273957B

The HIV Clinical Trials Market was valued at USD 1.15 billion in 2023, expected to reach USD 1.23 billion in 2024, and is projected to grow at a CAGR of 7.20%, to USD 1.88 billion by 2030.

The HIV clinical trials market encompasses a wide array of studies aiming to develop, test, and refine treatments and preventive measures for HIV and associated conditions. The scope of these trials includes evaluating the safety and efficacy of new antiretroviral drugs, vaccines, and investigational therapies, intending to improve patient outcomes and advance towards a potential cure or functional remission. The necessity for HIV clinical trials is underscored by the ongoing global HIV prevalence, changing viral landscapes, and resistance patterns, which necessitate continuous innovation and adaptation in therapeutic approaches. Applications of HIV clinical trials span across various phases, from early-stage drug development and proof-of-concept studies to late-stage trials focusing on long-term safety and comparative effectiveness. The end-use scope extends to pharmaceutical developers, healthcare providers, research institutions, and policy-makers aiming to implement evidence-based treatment protocols.

KEY MARKET STATISTICS
Base Year [2023] USD 1.15 billion
Estimated Year [2024] USD 1.23 billion
Forecast Year [2030] USD 1.88 billion
CAGR (%) 7.20%

The market is bolstered by factors such as advancements in biotechnology, increasing public and private funding, and heightened awareness of HIV. Potential opportunities include developing personalized medicine approaches leveraging genomic data, as well as exploring novel vaccine platforms and long-acting antiretrovirals. However, limitations such as high research costs, regulatory hurdles, ethical considerations regarding trial populations, and potential recruitment challenges pose significant barriers. Innovation can thrive in areas like machine learning for trial data analysis, incorporation of patient-centric trial designs utilizing virtual or decentralized methods, and exploring combination therapies that may provide synergistic benefits.

Key market growth factors include demographic shifts, particularly in high-incidence regions, and the emergence of integrative care models that emphasize both treatment and prevention. Businesses can benefit by investing in partnerships with academic institutions and patient advocacy groups to foster trust and enhance enrollment in trials. Overall, the dynamic and evolving nature of the HIV clinical trials market demands continual research and strategy adaption to harness technological advancements and patient needs effectively.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving HIV Clinical Trials Market

The HIV Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of AIDS disease worldwide
    • Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
  • Market Restraints
    • High costs associated with HIV clinical trials and associated research & development costs
  • Market Opportunities
    • Rising governmental approvals for HIV drugs and medications
    • Advancements in HIV clinical trial technologies and solutions
  • Market Challenges
    • Complexities in drug formulation of HIV clinical trials

Porter's Five Forces: A Strategic Tool for Navigating the HIV Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the HIV Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the HIV Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the HIV Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the HIV Clinical Trials Market

A detailed market share analysis in the HIV Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the HIV Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the HIV Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the HIV Clinical Trials Market

A strategic analysis of the HIV Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the HIV Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., American Gene Technologies Inc, AstraZeneca PLC, Bayer AG, BioNTech SE, Boehringer Ingelheim International GmbH, Cipla Ltd., CSL Limited, Daiichi Sankyo Company, Limited, Eli Lilly and Company, Emcure Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Moderna, Inc., Mylan N.V., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the HIV Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Phase, market is studied across Phase I, Phase II, Phase III, and Phase IV.
  • Based on Study Design, market is studied across Expanded Access Studies, Interventional Studies, and Observational Studies.
  • Based on Type of Intervention, market is studied across Drug Therapy and Vaccines.
  • Based on Participant, market is studied across Adults, Pediatric, and Pregnant Women.
  • Based on Sponsor, market is studied across Non Profit Organizations and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of AIDS disease worldwide
      • 5.1.1.2. Growing investment activities by pharmaceutical and non-profit organizations for HIV clinical trials
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with HIV clinical trials and associated research & development costs
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising governmental approvals for HIV drugs and medications
      • 5.1.3.2. Advancements in HIV clinical trial technologies and solutions
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities in drug formulation of HIV clinical trials
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Phase: Increasing the number of phase III clinical trials to make the new treatments available
    • 5.2.2. Sponsor: Increasing sponsorship from pharmaceutical & biopharmaceutical companies to enhance commercial availability of medications
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. HIV Clinical Trials Market, by Phase

  • 6.1. Introduction
  • 6.2. Phase I
  • 6.3. Phase II
  • 6.4. Phase III
  • 6.5. Phase IV

7. HIV Clinical Trials Market, by Study Design

  • 7.1. Introduction
  • 7.2. Expanded Access Studies
  • 7.3. Interventional Studies
  • 7.4. Observational Studies

8. HIV Clinical Trials Market, by Type of Intervention

  • 8.1. Introduction
  • 8.2. Drug Therapy
  • 8.3. Vaccines

9. HIV Clinical Trials Market, by Participant

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Pediatric
  • 9.4. Pregnant Women

10. HIV Clinical Trials Market, by Sponsor

  • 10.1. Introduction
  • 10.2. Non Profit Organizations
  • 10.3. Pharmaceutical & Biopharmaceutical Companies

11. Americas HIV Clinical Trials Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific HIV Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa HIV Clinical Trials Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Clinical Trial by AIDS Clinical Trials Group Seeks to Enhance HIV Treatment Efficacy and Safety
    • 14.3.2. Study Shows Injectable Cabotegravir Surpasses Oral PrEP in HIV Prevention Across Diverse Groups
    • 14.3.3. ReiThera, Ragon Institute, and IAVI Launch Phase I Trials for Innovative T-Cell HIV Vaccine, HIVconsvX
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. American Gene Technologies Inc
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. BioNTech SE
  • 6. Boehringer Ingelheim International GmbH
  • 7. Cipla Ltd.
  • 8. CSL Limited
  • 9. Daiichi Sankyo Company, Limited
  • 10. Eli Lilly and Company
  • 11. Emcure Pharmaceuticals Ltd.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. Gilead Sciences, Inc.
  • 14. GlaxoSmithKline plc
  • 15. Janssen Pharmaceuticals, Inc.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Merck & Co., Inc.
  • 18. Moderna, Inc.
  • 19. Mylan N.V.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Regeneron Pharmaceuticals, Inc.
  • 23. Sanofi S.A.
  • 24. Sun Pharmaceutical Industries Limited
  • 25. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. HIV CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. HIV CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HIV CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HIV CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EXPANDED ACCESS STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTERVENTIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY OBSERVATIONAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PREGNANT WOMEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON PROFIT ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY STUDY DESIGN, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY TYPE OF INTERVENTION, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY PARTICIPANT, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM HIV CLINICAL TRIALS MARKET SIZE, BY SPONSOR, 2018-2030 (USD MILLION)
  • TABLE 235. HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023